UBS Maintains Neutral on LifeStance Health Gr, Lowers Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Kevin Caliendo maintains a Neutral rating on LifeStance Health Group (NASDAQ:LFST) and lowers the price target from $9 to $7.5.
August 15, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Kevin Caliendo maintains a Neutral rating on LifeStance Health Group (NASDAQ:LFST) and lowers the price target from $9 to $7.5.
The lowered price target from $9 to $7.5 by UBS suggests a less optimistic outlook for LifeStance Health Group, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100